Molecular Subtyping in Breast Cancer

Clinical Pearls

Massimo Cristofanilli, MD, director, Breast Care Center, Jefferson University Hospitals, discusses molecular subtyping in the diagnosis and treatment of breast cancer.

• ASCO and CAP are trying to better define patients who may benefit from treatment with targeted therapies
• The current method of detecting HER2 overexpression/amplification may miss a portion of patients; molecular subtyping is a more accurate way to identify these patients
• A different molecular profiling signature should be offered to patients who are defined by current guidelines as 'borderline'

<<<

Back to the conference page